Comparison of 18F-FLT PET and 18F-FDG PET in esophageal cancer.

UNLABELLED 18F-FDG PET has gained acceptance for staging of esophageal cancer. However, FDG is not tumor specific and false-positive results may occur by accumulation of FDG in benign tissue. The tracer 18F-fluoro-3'-deoxy-3'-L-fluorothymidine (18F-FLT) might not have these drawbacks. The aim of this study was to investigate the feasibility of 18F-FLT PET for the detection and staging of esophageal cancer and to compare 18F-FLT PET with 18F-FDG PET. Furthermore, the correlation between 18F-FLT and 18F-FDG uptake and proliferation of the tumor was investigated. METHODS Ten patients with biopsy-proven cancer of the esophagus or gastroesophageal junction were staged with CT, endoscopic ultrasonography, and ultrasound of the neck. In addition, all patients underwent a whole-body 18F-FLT PET and 18F-FDG PET. Standardized uptake values were compared with proliferation expressed by Ki-67 positivity. RESULTS 18F-FDG PET was able to detect all esophageal cancers, whereas 18F-FLT PET visualized the tumor in 8 of 10 patients. Both 18F-FDG PET and 18F-FLT PET detected lymph node metastases in 2 of 8 patients. 18F-FDG PET detected 1 cervical lymph node that was missed on 18F-FLT PET, whereas 18F-FDG PET showed uptake in benign lesions in 2 patients. The uptake of 18F-FDG (median standardized uptake value [SUV(mean)], 6.0) was significantly higher than 18F-FLT (median SUV(mean), 3.4). Neither 18F-FDG maximum SUV (SUV(max)) nor 18F-FLT SUV(max) correlated with Ki-67 expression in the linear regression analysis. CONCLUSION In this study, uptake of 18F-FDG in esophageal cancer is significantly higher compared with 18F-FLT uptake. 18F-FLT scans show more false-negative findings and fewer false-positive findings than do 18F-FDG scans. Uptake of 18F-FDG or 18F-FLT did not correlate with proliferation.

[1]  Ludwig G. Strauss,et al.  Fluorine-18 deoxyglucose and false-positive results: a major problem in the diagnostics of oncological patients , 1996, European Journal of Nuclear Medicine.

[2]  Fons Bongaerts,et al.  Detection of distant metastases in esophageal cancer with (18)F-FDG PET. , 2004, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[3]  D. Bowrey,et al.  The role of staging investigations for oesophago-gastric carcinoma. , 2004, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[4]  Wolfgang A Weber,et al.  Time course of tumor metabolic activity during chemoradiotherapy of esophageal squamous cell carcinoma and response to treatment. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  W. Vaalburg,et al.  Detection and Grading of Soft Tissue Sarcomas of the Extremities with 18F-3′-Fluoro-3′-Deoxy-l-Thymidine , 2004, Clinical Cancer Research.

[6]  Gerald Reischl,et al.  PET with [18F]fluorothymidine for imaging of primary breast cancer: a pilot study , 2004, European Journal of Nuclear Medicine and Molecular Imaging.

[7]  W. Vaalburg,et al.  18F-FLT PET for visualization of laryngeal cancer: comparison with 18F-FDG PET. , 2004, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[8]  D. Visvikis,et al.  Comparison of methodologies for the in vivo assessment of 18FLT utilisation in colorectal cancer , 2004, European Journal of Nuclear Medicine and Molecular Imaging.

[9]  H. Hoekstra,et al.  3'-18F-fluoro-3'-deoxy-L-thymidine: a new tracer for staging metastatic melanoma? , 2003, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[10]  K. Krohn,et al.  Monitoring tumor cell proliferation by targeting DNA synthetic processes with thymidine and thymidine analogs. , 2003, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[11]  Pieter L. Jager,et al.  Pitfalls of Positive Findings in Staging Esophageal Cancer With F-18-Fluorodeoxyglucose Positron Emission Tomography , 2003, Annals of Surgical Oncology.

[12]  Torsten Mattfeldt,et al.  Imaging proliferation in lung tumors with PET: 18F-FLT versus 18F-FDG. , 2003, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[13]  H. Dittmann,et al.  [18F]FLT PET for diagnosis and staging of thoracic tumours , 2003, European Journal of Nuclear Medicine and Molecular Imaging.

[14]  Byung-Tae Kim,et al.  Metastasis to regional lymph nodes in patients with esophageal squamous cell carcinoma: CT versus FDG PET for presurgical detection prospective study. , 2003, Radiology.

[15]  D. Visvikis,et al.  Potential impact of [18F]3'-deoxy-3'-fluorothymidine versus [18F]fluoro-2-deoxy-d-glucose in positron emission tomography for colorectal cancer , 2003, European Journal of Nuclear Medicine and Molecular Imaging.

[16]  石守 崇好.  Increased 18F-FDG uptake in a model of inflammation : Concanavalin A-mediated lymphocyte activation , 2003 .

[17]  Y. Yonekura,et al.  Basis of FLT as a cell proliferation marker: comparative uptake studies with [3H]thymidine and [3H]arabinothymidine, and cell-analysis in 22 asynchronously growing tumor cell lines. , 2002, Nuclear medicine and biology.

[18]  H. Kuwano,et al.  Comparison between positron emission tomography and computed tomography in the use of the assessment of esophageal carcinoma , 2002, Cancer.

[19]  U. Haberkorn,et al.  [18F]FLT; portrait of a proliferation marker. , 2002, European journal of nuclear medicine and molecular imaging.

[20]  Michael E Phelps,et al.  Positron emission tomography scanning: current and future applications. , 2002, Annual review of medicine.

[21]  J. Pruim,et al.  Carbon-11 choline or FDG-PET for staging of oesophageal cancer? , 2001, European Journal of Nuclear Medicine.

[22]  J. Moley,et al.  Strategy for identification of novel glucose transporter family members by using internet-based genomic databases. , 2000, Surgery.

[23]  P. Dupont,et al.  Utility of positron emission tomography for the staging of patients with potentially operable esophageal carcinoma. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  Rice Tw.  Clinical staging of esophageal carcinoma. CT, EUS, and PET. , 2000 .

[25]  Johannes Gerdes,et al.  The Ki‐67 protein: From the known and the unknown , 2000, Journal of cellular physiology.

[26]  J. R. Grierson,et al.  Simplified Labeling Approach for Synthesizing 3′-Deoxy-3′-[18F]fluorothymidine ([18F]FLT) , 2000 .

[27]  T. Rice.  Clinical staging of esophageal carcinoma. CT, EUS, and PET. , 2000, Chest surgery clinics of North America.

[28]  M. Defrise,et al.  Attenuation correction in whole-body FDG oncological studies: the role of statistical reconstruction , 1999, European Journal of Nuclear Medicine.

[29]  Otto Muzik,et al.  Imaging proliferation in vivo with [F-18]FLT and positron emission tomography , 1998, Nature Medicine.

[30]  T Ido,et al.  Intratumoral distribution of fluorine-18-fluorodeoxyglucose in vivo: high accumulation in macrophages and granulation tissues studied by microautoradiography. , 1992, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[31]  T. Chou,et al.  Comparisons of anti-human immunodeficiency virus activities, cellular transport, and plasma and intracellular pharmacokinetics of 3'-fluoro-3'-deoxythymidine and 3'-azido-3'-deoxythymidine , 1992, Antimicrobial Agents and Chemotherapy.

[32]  S. Eriksson,et al.  Diverging substrate specificity of pure human thymidine kinases 1 and 2 against antiviral dideoxynucleosides. , 1991, The Journal of biological chemistry.

[33]  L. Sobin,et al.  TNM Classification of Malignant Tumours , 1987, UICC International Union Against Cancer.

[34]  K. Hamacher,et al.  Efficient stereospecific synthesis of no-carrier-added 2-[18F]-fluoro-2-deoxy-D-glucose using aminopolyether supported nucleophilic substitution. , 1986, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.